Drug profile · INN
tenofovir alafenamide
VEMLIDY
tenofovir alafenamide (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — tenofovir alafenamide
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
tenofovir alafenamide (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tenofovir alafenamide?
tenofovir alafenamide (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tenofovir alafenamide?
VEMLIDY is a marketed brand name for tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tenofovir alafenamide?
tenofovir alafenamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.